

## Anatomical Regions XW0-XW2

**X** New Technology

**W** Anatomical Regions

**0** **Introduction:** Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

Body Part Character 4	Approach Character 5	Device/Substance/Technology Character 6	Qualifier Character 7
1 Subcutaneous Tissue	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
1 Subcutaneous Tissue	3 Percutaneous	H Other New Technology Monoclonal Antibody K Leronlimab Monoclonal Antibody S COVID-19 Vaccine Dose 1 T COVID-19 Vaccine Dose 2 U COVID-19 Vaccine	6 New Technology Group 6
1 Subcutaneous Tissue	3 Percutaneous	W Caplacizumab	5 New Technology Group 5
2 Muscle	3 Percutaneous	S COVID-19 Vaccine Dose 1 T COVID-19 Vaccine Dose 2 U COVID-19 Vaccine	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	0 Brexanolone	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	2 Ceftazidime-Avibactam Anti-infective	1 New Technology Group 1
3 Peripheral Vein	3 Percutaneous	2 Nerinitide	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	3 Idarucizumab, Dabigatran Reversal Agent	1 New Technology Group 1
3 Peripheral Vein	3 Percutaneous	3 Durvalumab Antineoplastic	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	4 Isavuconazole Anti-infective 5 Blinatumomab Antineoplastic Immunotherapy	1 New Technology Group 1
3 Peripheral Vein	3 Percutaneous	6 Lefamulin Anti-infective	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated 9 Defibrotide Sodium Anticoagulant	2 New Technology Group 2
3 Peripheral Vein	3 Percutaneous	9 Ceftolozane/Tazobactam Anti-infective	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	A Bezlotoxumab Monoclonal Antibody	3 New Technology Group 3
3 Peripheral Vein	3 Percutaneous	A Cefiderocol Anti-infective	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
3 Peripheral Vein	3 Percutaneous	B Omadacycline Anti-infective	6 New Technology Group 6
3 Peripheral Vein <sup>MO</sup>	3 Percutaneous	C Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy	3 New Technology Group 3
3 Peripheral Vein	3 Percutaneous	C Eculizumab D Atezolizumab Antineoplastic	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
3 Peripheral Vein	3 Percutaneous	E Etesevimab Monoclonal Antibody	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
3 Peripheral Vein	3 Percutaneous	F Bamlanivimab Monoclonal Antibody	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	G Plazomicin Anti-infective	4 New Technology Group 4

XW0 continued on next page

<sup>LC</sup> Limited Coverage <sup>NC</sup> Noncovered <sup>HAC</sup> HAC-associated Procedure <sup>CC</sup> Combination Cluster - See Appendix G for code lists


<sup>MO</sup> Non-OR-Affecting MS-DRG Assignment <sup>NR</sup> New/Revised Text in Orange <sup>M</sup> Male <sup>F</sup> Female

## X New Technology

XWO continued from previous page

## W Anatomical Regions

0 Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

Body Part	Approach	Device/Substance/Technology	Qualifier
Character 4	Character 5	Character 6	Character 7
3 Peripheral Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
3 Peripheral Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	H Synthetic Human Angiotensin II	4 New Technology Group 4
3 Peripheral Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5
3 Peripheral Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	K Fosfomycin Anti-infective	5 New Technology Group 5
3 Peripheral Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	N Meropenem-vaborbactam Anti-infective Q Tagraxofusp-erzs Antineoplastic S Iobenguane I-131 Antineoplastic U Imipenem-cilastatin- relebactam Anti-infective W Caplacizumab	5 New Technology Group 5
4 Central Vein	3 Percutaneous	0 Brexanolone	6 New Technology Group 6
4 Central Vein	3 Percutaneous	2 Ceftazidime-Avibactam Anti-infective	1 New Technology Group 1
4 Central Vein	3 Percutaneous	2 Nerinitide	6 New Technology Group 6
4 Central Vein	3 Percutaneous	3 Idarucizumab, Dabigatran Reversal Agent	1 New Technology Group 1
4 Central Vein	3 Percutaneous	3 Durvalumab Antineoplastic	6 New Technology Group 6
4 Central Vein	3 Percutaneous	4 Isavuconazole Anti-infective 5 Blinatumomab Antineoplastic Immunotherapy	1 New Technology Group 1
4 Central Vein	3 Percutaneous	6 Lefamulin Anti-infective	6 New Technology Group 6
4 Central Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated 9 Defibrotide Sodium Anticoagulant	2 New Technology Group 2
4 Central Vein	3 Percutaneous	9 Ceftolozane/Tazobactam Anti-infective	6 New Technology Group 6
4 Central Vein	3 Percutaneous	A Bezlotoxumab Monoclonal Antibody	3 New Technology Group 3
4 Central Vein	3 Percutaneous	A Cefiderocol Anti-infective	6 New Technology Group 6
4 Central Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
4 Central Vein	3 Percutaneous	B Omadacycline Anti-infective	6 New Technology Group 6
4 Central Vein 	3 Percutaneous	C Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy	3 New Technology Group 3
4 Central Vein	3 Percutaneous	C Eculizumab D Atezolizumab Antineoplastic	6 New Technology Group 6
4 Central Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
4 Central Vein	3 Percutaneous	E Etesevimab Monoclonal Antibody	6 New Technology Group 6
4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
4 Central Vein	3 Percutaneous	F Bamlanivimab Monoclonal Antibody	6 New Technology Group 6

XWO continued on next page

 Limited Coverage  Noncovered  HAC-associated Procedure  Combination Cluster - See Appendix G for code lists

 Non-OR-Affecting MS-DRG Assignment  New/Revised Text in Orange  Male  Female

**X New Technology**

XW0 continued from previous page

**W Anatomical Regions**

**0 Introduction:** Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

Body Part Character 4	Approach Character 5	Device/Substance/Technology Character 6	Qualifier Character 7
4 Central Vein	3 Percutaneous	G Plazomicin Anti-infective	4 New Technology Group 4
4 Central Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
4 Central Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
4 Central Vein	3 Percutaneous	H Synthetic Human Angiotensin II	4 New Technology Group 4
4 Central Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5
4 Central Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6
4 Central Vein	3 Percutaneous	K Fosfomycin Anti-infective	5 New Technology Group 5
4 Central Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6
4 Central Vein	3 Percutaneous	N Meropenem-vaborbactam Anti-infective Q Tagraxofusp-erzs Antineoplastic S lobenguane I-131 Antineoplastic U Imipenem-cilastatin- relebactam Anti-infective W Caplacizumab	5 New Technology Group 5
9 Nose	7 Via Natural or Artificial Opening	M Esketamine Hydrochloride	5 New Technology Group 5
D Mouth and Pharynx	X External	6 Lefamulin Anti-infective	6 New Technology Group 6
D Mouth and Pharynx	X External	8 Uridine Triacetate	2 New Technology Group 2
D Mouth and Pharynx	X External	F Other New Technology Therapeutic Substance J Apalutamide Antineoplastic L Erdafitinib Antineoplastic	5 New Technology Group 5
D Mouth and Pharynx	X External	M Baricitinib	6 New Technology Group 6
D Mouth and Pharynx	X External	R Venetoclax Antineoplastic T Ruxolitinib V Gilteritinib Antineoplastic	5 New Technology Group 5
G Upper GI H Lower GI	7 Via Natural or Artificial Opening	M Baricitinib	6 New Technology Group 6
G Upper GI H Lower GI	8 Via Natural or Artificial Opening Endoscopic	8 Mineral-based Topical Hemostatic Agent	6 New Technology Group 6
Q Cranial Cavity and Brain	3 Percutaneous	1 Eladocogene exuparvovec	6 New Technology Group 6

Ⓜ XW033C3 XW043C3

**X New Technology**

**W Anatomical Regions**

**1 Transfusion:** Putting in blood or blood products

Body Part Character 4	Approach Character 5	Device/Substance/Technology Character 6	Qualifier Character 7
3 Peripheral Vein 4 Central Vein	3 Percutaneous	2 Plasma, Convalescent (Nonautologous)	5 New Technology Group 5

**X New Technology**

**W Anatomical Regions**

**2 Transfusion:** Putting in blood or blood products

Body Part Character 4	Approach Character 5	Device/Substance/Technology Character 6	Qualifier Character 7
3 Peripheral Vein 4 Central Vein	3 Percutaneous	4 Brexucabtagene Autoleucl Immunotherapy 7 Lisocabtagene Maraleucl Immunotherapy	6 New Technology Group 6

Ⓜ Limited Coverage Ⓝ Noncovered Ⓜ HAC-associated Procedure Ⓜ Combination Cluster - See Appendix G for code lists

Ⓜ Non-OR-Affecting MS-DRG Assignment New/Revised Text in Orange ♂ Male ♀ Female